Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination
Clinical trial NCT05124171 · UNKNOWN
Trial details
- NCT number
- NCT05124171
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-08
- Primary completion
- 2022-12-01
- Enrollment
- 247
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.